mRNA |
tanespimycin:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.072 |
0.07 |
mRNA |
AZD6482 |
CTRPv2 |
pan-cancer |
AAC |
0.07 |
0.07 |
mRNA |
navitoclax:pluripotin (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.068 |
0.07 |
mRNA |
KU 0060648 |
CTRPv2 |
pan-cancer |
AAC |
0.067 |
0.07 |
mRNA |
BRD-K07442505 |
CTRPv2 |
pan-cancer |
AAC |
0.07 |
0.07 |
mRNA |
AZD6244 |
CTRPv2 |
pan-cancer |
AAC |
0.066 |
0.08 |
mRNA |
Irinotecan |
gCSI |
pan-cancer |
AAC |
-0.095 |
0.08 |
mRNA |
MS-275 |
CTRPv2 |
pan-cancer |
AAC |
0.059 |
0.08 |
mRNA |
Compound 23 citrate |
CTRPv2 |
pan-cancer |
AAC |
0.061 |
0.08 |
mRNA |
PLX4720 |
CTRPv2 |
pan-cancer |
AAC |
0.063 |
0.08 |